10th Product Development for Vaccine Research Committee (PDVAC) Meeting

132 lectures

Dates:  

12-13 December 2023

More than 120 participants attended this annual hybrid WHO meeting, with global, regional and country level representation of public health and immunization stakeholders, technical experts and vaccine product developers and manufacturers. The Product Development for Vaccines Advisory Committee (PDVAC) provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies. Please see more about PDVAC here.

Outcomes: 

The objectives of PDVAC 2024 meeting included:

• Related to IA2030 strategic priority 7, review the process of partnering with regions to identify global priority pathogens for new vaccines for development and investment, and endorse a proposed short-list of global endemic pathogen priorities for which new vaccines are needed (please see the list of endorsed pathogens for IA2030 below);
• Review the progress of pipeline vaccine and monoclonal antibody candidates against specific endemic pathogens, including those on the proposed global priority list, and provide strategic advice on the critical activities that are already ongoing and/or needed to advance new vaccine and monoclonals for priority endemic pathogens.

The vaccines discussed at PDVAC included: Group B streptococcus, Chikungunya, new TB vaccines, Shigella, non-typhoidal salmonella, and next generation malaria vaccines.

The progress of novel vaccine delivery innovations such as vaccine-microarray patches were also discussed. Several cross-cutting topics were discussed, including the role and current status of the Gavi Vaccine Investment Strategy process, and the strategic considerations for novel approaches to ease vaccine delivery, such as novel combination vaccines.

The meeting materials and the executive summary including PDVAC’s recommendations can be found here. 

Results of the global priority pathogens for new vaccine R&D (displayed reflecting the most advanced use case): Pathogen priorities for vaccine research: ¨ 

  • Group A Streptococcus 
  • Hepatitis C virus 
  • Klebsiella pneumoniae 
  • Leishmania spp
  • Staphylococcus aureus Pathogen priorities for vaccine product development 
  • Cytomegalovirus 
  • Group B Streptococcus 
  • HIV-1 
  • Influenza 
  • Non-typhoidal Salmonella 
  • Norovirus 
  • Plasmodium falciparum 
  • Shigella spp Pathogen priorities for preparation of vaccine policy: 
  • Dengue virus 
  • Extra-intestinal pathogenic E coli (ExPEC) 
  • Mycobacterium tuberculosis (TB) 
  • Respiratory syncytial virus (RSV) Please note that IVB’s PDVAC is already engaged, or may engage in the future on advancing vaccines and use cases where there is a public health need in low- and middle-income countries.
0